Adimab

Adimab is a leader in the discovery and engineering of fully human monoclonal and multispecific antibodies.

Founded in 2007 and headquartered in Lebanon, New Hampshire, with a secondary location in Mountain View, California, the company focuses on external partnerships for therapeutic antibody development. Adimab has partnered with over 140 pharmaceutical and biotechnology companies, generating more than 650 therapeutic programs and 89 clinical programs. The company utilizes a proprietary yeast-based antibody discovery platform that combines synthetic and immune libraries to produce highly specific and stable antibodies. Adimab offers a range of services, including naïve discovery, antibody engineering, and optimization, as well as AI and machine learning-guided library design. Its client base includes global pharmaceutical companies, biotechnology firms, and academic institutions, all benefiting from Adimab's expertise in advancing therapeutic candidates efficiently.